What "compounded semaglutide" actually means
Compounded semaglutide is an unapproved preparation. FDA does not review its safety, effectiveness and quality before marketing as it does approved products. An individual medical need may exist, but a prescription or pharmacy license does not demonstrate equivalence or guarantee safety. FDA.
A compounded preparation is not FDA-approved or established as equivalent to Ozempic or Wegovy. FDA recommends considering it only when an approved medicine cannot meet a patient’s medical needs. FDA.
Semaglutide sodium and semaglutide acetate are salt forms different from the ingredient in approved medicines. FDA states it is unaware of a lawful basis for their use in compounding. Verify the ingredient and instructions with the pharmacy; this guide does not verify a particular batch. FDA.
An individual prescription alone does not satisfy every legal condition. Restrictions on copies of commercially available medicines continue after the shortage. FDA.
503A vs 503B: the regulatory framework
Section 503A generally covers compounding for individual patients based on prescriptions. State authorities oversee traditional pharmacies, and FDA retains authority over federal requirements. Section 503B outsourcing facilities register with FDA, follow cGMP and undergo risk-based inspections. They may supply clinics without individual prescriptions when the other conditions are met. Neither category approves the product. FDA.
The FDA 2025 shortage resolution — what changed
- February 21, 2025: FDA declared the semaglutide injection shortage resolved.
- April 24, 2025: the court decision ended the shortage-related enforcement discretion period for 503A. The 503B period ended May 22, 2025.
FDA’s April 1, 2026 update explains that a 503A change must produce a significant difference for an identified patient, as determined and documented by the prescriber, to fall outside the relevant copy definition. A different dose or added B12 does not automatically create that exception. FDA.
The same update states semaglutide and tirzepatide are on neither the 503B bulks list nor the shortage list. Registration as a 503B facility therefore is not blanket authorization to compound them from bulk substances. The pharmacy and prescriber must satisfy the applicable requirements. FDA.
What the safety evidence actually shows
Wegovy and Ozempic trials study specific finished products; their results do not establish the safety or effectiveness of a compounded preparation. The preparation’s quality and directions matter. Wegovy labeling.
FDA has received reports of dosing errors and other adverse events with compounded semaglutide, including some hospitalizations. Incomplete reporting does not provide a reliable incidence rate or prove a supply channel is lower risk. Ask for clear concentration, dose, syringe and storage instructions. FDA.
Contraindications every prescriber should screen
Wegovy and Zepbound labeling contraindicates use with a personal or family history of medullary thyroid carcinoma (MTC), MEN 2, or hypersensitivity to the product. Other conditions call for specific precautions rather than a blanket contraindication.
- Pregnancy: weight loss offers no benefit during pregnancy. Discuss pregnancy plans; semaglutide should be stopped at least two months before a planned pregnancy. Breastfeeding decisions depend on the product and individual circumstances.
- Digestive symptoms, pancreas and gallbladder: disclose pancreatitis, gallstones and gastroparesis. These products are not recommended with severe gastroparesis. Severe persistent abdominal pain needs urgent medical assessment.
- Kidneys, glucose and eyes: vomiting or diarrhea can cause dehydration and kidney injury. Insulin and sulfonylureas increase hypoglycemia risk. Diabetic retinopathy may need monitoring.
- Other treatment: do not combine GLP-1 medicines on your own. Tell clinicians about planned anesthesia. With tirzepatide, discuss additional or non-oral contraception for four weeks after starting and after each dose increase.
A compounded preparation also requires assessment of its ingredients, concentration and preparation-specific risks. Approved-product warnings do not establish equivalent safety. Wegovy labeling.
Read the product-specific tirzepatide precautions as well. Zepbound labeling.
7-point checklist to evaluate a compounded GLP-1 provider
- Verify the prescriber’s license for your state.
- Confirm the dispensing pharmacy’s name and license.
- Ask why an approved medicine cannot meet your needs.
- Review concentration, dose, syringe, storage and beyond-use date.
- Agree on adverse-effect reporting and follow-up.
- Compare billing period, total upfront payment and cancellation terms.
- Verify claimed certifications without treating them as drug approval.
How REMEVi handles each of these
To assess REMEVi, review the care team, pharmacy information and plans and full payments. Ask for your prescriber and pharmacy details before starting. Platform certification does not approve the preparation or guarantee outcomes.
Compare the full cost.
These are REMEVi compounded program prices. Brand prices depend on the prescribed product, coverage and savings eligibility. Four weeks means 28 days, not a calendar month.
Semaglutide
Prescribed medication if approved, clinician evaluation and follow-up, shipping and bilingual support are included. Lab tests required by your clinician for the GLP-1 program are included in your plan price.
The monthly plan is billed every 4 weeks. The 12-week and 24-week plans are prepaid for the full term, with the total charge shown before you choose. Review the renewal terms at checkout and in your patient portal. You can cancel future renewals without a cancellation fee. Prepaid terms are paid in advance; refund eligibility is governed by the Cancellation & Refund Policy.
All plans & included care · Semaglutide cost breakdown · Refund terms
Make your next conversation useful.
Keep a list of your medicines, symptoms and questions. Treatment is an ongoing clinical decision, with dose changes guided by the prescriber. A study average is not a personal target or a deadline.
- Why is this exact medicine appropriate for my history and goals?
- If it is compounded, why can an approved medicine not meet my medical needs?
- What is my dose, concentration, syringe and schedule? What happens after a missed dose?
- Which symptoms need a message, a same-day call or emergency care?
- When will we review progress, nutrition, strength and tolerability?
- Who prescribes and dispenses my medication, and how do I reach them?
Common questions.
Does a prescription guarantee a compounded product is safe?
Compounded preparations are not FDA-approved or established as equivalent to brand products. FDA recommends considering them only when an approved medicine cannot meet a patient’s medical needs. Evaluation and prescribing are individual.
What should I verify about the pharmacy?
Confirm the pharmacy’s name and license, prescribed preparation, concentration, dose, storage instructions and beyond-use date. If any instruction is unclear, ask the pharmacy or your clinician before using it.
Does platform certification mean FDA approval?
No. Platform certification does not approve a medicine or establish the safety, effectiveness or quality of a specific preparation.
Which side effects need attention?
Nausea, vomiting, diarrhea or constipation can occur, particularly during dose increases. Severity and duration vary. Seek medical care for severe persistent abdominal pain, inability to keep fluids down or symptoms of a serious allergic reaction. Do not change your dose on your own.
How should I compare costs?
REMEVi semaglutide: From $159 per 4 weeks with the 24-week plan: $954 paid upfront. Or $199 every 4 weeks without a long-term prepayment. REMEVi tirzepatide: From $225 per 4 weeks with the 24-week plan: $1,350 paid upfront. Or $269 every 4 weeks without a long-term prepayment. Four weeks is not a calendar month. Brand products may have different costs depending on insurance, presentation and savings eligibility.
Sources & review history.
- FDA: unapproved GLP-1 products and patient safety
- FDA: compounding questions and answers
- FDA: post-shortage compounding requirements (April 2026 update)
- Wegovy: prescribing information
- Zepbound: prescribing information
Previous medical review: · Medical team. Editorial update: September 17, 2026. Educational information; not individual medical advice or a new medical review. Editorial policy.